Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Augsburg – page 3

300 clinical trials in Augsburg, Germany across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Augsburg at a glance
300
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

300 trials in Augsburg

Open in trial search

Chronic myeloid leukaemia

Recruiting

Long-Term Safety Study of Asciminib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bosutinib
  • Sponsor:Novartis Pharma AG

Neoplasm

Recruiting

EIK1005 Alone and with Pembrolizumab for Advanced Solid Tumors in Patients with MSI-H or dMMR Tumors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Eikon Therapeutics Inc.

Triple negative breast cancer+4

Recruiting

Neoadjuvant Sacituzumab Govitecan and Pembrolizumab for Patients with Clinical Stage II-III Triple-Negative Early Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:WSG Women's Cancer Study Group GmbH

Acute promyelocytic leukaemia

Recruiting

QTX-2101 and Arsenic Trioxide in Adult Patients With Acute Promyelocytic Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Arsenic Trioxide

IgA nephropathy

Recruiting

Long-Term Safety Study of Zigakibart in Adults with IgA Nephropathy Who Have Completed Previous Zigakibart Trials

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Zigakibart
  • Sponsor:Novartis Pharma AG

Renal cell carcinoma

Recruiting

Belzutifan and Zanzalintinib in Adults with Advanced Renal Cell Carcinoma After PD-1/L1 and VEGF-TKI Therapy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC

Vitamin D deficiency+1

Recruiting

High-Dose Colecalciferol for 28-Day Mortality in Critically Ill Adults with Severe Vitamin D Deficiency

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Colecalciferol
  • Sponsor:Medical University Of Graz

Acute kidney injury+2

Recruiting

Effect of sodium hydrogen carbonate on kidney health in critically ill patients with metabolic acidosis and acute kidney injury

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Malic acid
  • Sponsor:Universitaet Muenster

Glioma

Recruiting

A study of ulixertinib, tovorafenib, and vinblastine sulfate for children with progressive, relapsed, or refractory low-grade glioma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Tovorafenib
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Breast cancer+4

Recruiting

Study of elacestrant and ribociclib compared to standard treatment for patients with high-risk ER+/HER2- early breast cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Elacestrant
  • Sponsor:WSG Women's Cancer Study Group GmbH

Short stature+1

Recruiting

Study of Lonapegsomatrin and Somatropin in Children and Adolescents with Short Stature or Growth Failure due to Turner Syndrome, SHOX Deficiency, SGA, or Idiopathic Short Stature

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Lonapegsomatropin
  • Sponsor:Ascendis Pharma Endocrinology Division A/S

Clostridium difficile infection

Recruiting

A study to evaluate the effectiveness of AZD5148 in preventing the recurrence of Clostridioides difficile infection in adults.

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD5148
  • Sponsor:AstraZeneca AB

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Augsburg

What the registry says about research in the country

01 Oncology Research

Groundbreaking trials focusing on breast cancer, lung cancer, and lymphoma treatments. Studies evaluating novel therapeutic approaches including targeted therapies and immunotherapy combinations.

  • HR-positive breast cancer treatment evaluation
  • Advanced non-small cell lung cancer therapies
  • Lymphoma and leukemia interventions

Several trials are investigating combination therapies to improve patient outcomes in various cancer types.

02 Dermatology Studies

Comprehensive research into plaque psoriasis and atopic dermatitis, with multiple trials testing new therapeutic agents and preventive approaches.

  • Moderate to severe psoriasis treatments
  • Preventive interventions for atopic dermatitis
  • Long-term safety assessments

Focus on both treatment and prevention strategies for chronic skin conditions.

03 Gastrointestinal Research

Innovative studies addressing ulcerative colitis and gastroparesis, testing novel therapeutic approaches and treatment combinations.

  • Ulcerative colitis treatment optimization
  • Gastroparesis symptom management
  • Biliary tract cancer therapies

Trials aim to improve quality of life and treatment outcomes for patients with chronic digestive conditions.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.